Table 2.
Characteristics of patients enrolled and not enrolled in the study
| Characteristic | Enrolled (n = 100) | Declined (n = 21) | P -value | |
|---|---|---|---|---|
| Median age in years (range) | 5.1 (0.1-17.0) | 4.0 (0.1-14.2) | 0.73 | |
| Female gender | 45 (45%) | 5 (24%) | 0.09 | |
| Ethnicity | 1a | |||
| Hispanic | 43 (43%) | 10 (48%) | ||
| Non-Hispanic | 51 (51%) | 11 (52%) | ||
| Not reported | 6 (6%) | - | ||
| Race | 0.17b | |||
| White | 56 (56%) | 18 (85%) | ||
| Black or African American | 12 (12%) | 1 (5%) | ||
| Asian | 4 (4%) | 1 (5%) | ||
| American Indian or Alaska Native | 4 (4%) | 1 (5%) | ||
| Multiple | 6 (6%) | - | ||
| Not reported | 18 (18%) | - | ||
| Tumor location | 0.22 | |||
| CNS | 33 (33%) | 10 (48%) | ||
| Non-CNS | 67 (67%) | 11 (52%) | ||
| Tumor metastatic at diagnosis | 34 (34%) | ND | ||
| Adjuvant tumor treatment planned | 82 (82%) | ND | ||
| Tumor available for WES | 84 (84%) | 14 (67%) | 0.12 | |
| Interpreter and Spanish consent form used | 15 (15%) | 4 (19%) | 0.74 | |
| Median days from surgery to study decision (range) | 36 (5-63) | 42 (20-61) | 0.052 | |
a P-value was calculated with ‘Not reported’ subjects excluded. bComparison was made between ‘White’ versus others with ‘Not reported’ subjects excluded. Two sample rank sum tests were used to compare the continuous data and Fisher’s exact tests were used for the categorical data. CNS, central nervous system; ND, not determined; WES, whole exome sequencing.